Trials / Completed
CompletedNCT00193349
Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer
Phase II Evaluation of Gleevec Combined With Camptosar Plus Paraplatin in Patients With Previously Untreated Extensive Stage SCLC
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (planned)
- Sponsor
- SCRI Development Innovations, LLC · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate combination chemotherapy for patients with extensive stage small cell lung cancer combined with the potentially useful growth inhibiting effects of Gleevec.
Detailed description
Upon determination of eligibility, all patients will be receive: * Irinotecan + Carboplatin + Imatinib
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imatinib | |
| DRUG | Irinotecan | |
| DRUG | Carboplatin |
Timeline
- Start date
- 2002-09-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2005-09-19
- Last updated
- 2010-06-28
Source: ClinicalTrials.gov record NCT00193349. Inclusion in this directory is not an endorsement.